Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

ASTRAZENECA PHARMA INDIA LTD.

NSE : ASTRAZENBSE : 506820ISIN CODE : INE203A01020Industry : Pharmaceuticals & DrugsHouse : Astrazeneca Pharma India - MNC

BSE5415.40115.4 (+2.18 %)

PREV CLOSE ( ) 5300.00

OPEN PRICE ( ) 5381.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 1499

TODAY'S LOW / HIGH ( )5349.25 5514.70

52 WK LOW / HIGH ( )3128.5 7208

NSE5425.8093.55 (+1.75 %)

PREV CLOSE( ) 5332.25

OPEN PRICE ( ) 5377.00

BID PRICE (QTY) 5425.80 (55)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 11479

TODAY'S LOW / HIGH( ) 5335.35 5520.00

52 WK LOW / HIGH ( )3125 7220.95

Select year

(Rs.in Million)

Particulars

Mar 2023

Mar 2022

Mar 2021

Mar 2020

Mar 2019

Profit Before Tax

1341.00

830.40

1270.90

1139.70

726.70

Adjustment

-48.00

96.60

142.00

97.50

76.20

Changes In working Capital

-301.90

328.90

-39.50

-26.60

98.10

Cash Flow after changes in Working Capital

991.10

1255.90

1373.40

1210.60

901.00

Cash Flow from Operating Activities

582.90

1008.00

1047.80

874.20

549.80

Cash Flow from Investing Activities

181.10

47.40

1730.30

-1708.00

42.80

Cash Flow from Financing Activities

-244.80

-94.60

-89.70

-63.60

Net Cash Inflow / Outflow

519.20

960.80

2688.40

-897.40

592.60

Opening Cash & Cash Equivalents

4484.20

3523.40

835.00

1732.40

1139.80

Cash & Cash Equivalent on Amalgamation / Take over / Merger

Cash & Cash Equivalent of Subsidiaries under liquidations

Translation adjustment on reserves / op cash balalces frgn subsidiaries

Effect of Foreign Exchange Fluctuations

Closing Cash & Cash Equivalent

5003.40

4484.20

3523.40

835.00

1732.40